Vivos Therapeutics Inc (VVOS) - Total Liabilities
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has total liabilities worth $26.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vivos Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Vivos Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Vivos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Vivos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perrot Duval Holding SA
SW:PEDU
|
Switzerland | CHF5.52 Million |
|
International Graphite Ltd
AU:IG6
|
Australia | AU$4.59 Million |
|
Diamond Estates Wines & Spirits Inc
V:DWS
|
Canada | CA$23.76 Million |
|
Lupaka Gold Corp.
V:LPK
|
Canada | CA$408.58K |
|
Lions Bay Capital Inc
V:LBI
|
Canada | CA$2.59 Million |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
USA | $18.25 Million |
|
Advanced Blockchain AG
XETRA:BWQ
|
Germany | €142.78 Million |
|
Ajooni Biotech Limited
NSE:AJOONI
|
India | Rs226.46 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Vivos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VVOS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -23.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Vivos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.70 Million | +264.28% |
| 2024-12-31 | $7.33 Million | -28.97% |
| 2023-12-31 | $10.32 Million | +15.70% |
| 2022-12-31 | $8.92 Million | +9.44% |
| 2021-12-31 | $8.15 Million | -3.09% |
| 2020-12-31 | $8.41 Million | -19.86% |
| 2019-12-31 | $10.49 Million | +210.75% |
| 2018-12-31 | $3.38 Million | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more